SYNERGETIC ANTINEOPLASTIC ACTION OF DOXORUBICIN AND FULLERENE C60 AS MEANS OF ITS DELIVERY TOWARDS HUMAN CANCER CELLS IN VITRO: CELLULAR AND MOLECULAR MECHANISMS

R. R. Panchuk, V. V. Chumak, N. R. Skorokhyd, L. V. Lehka, S. V. Prylutska, W. Berger, P. Heffeter, R. S. Stoika, Yu. I. Prylutsky


DOI: http://dx.doi.org/10.30970/sbi.0701.240

Abstract


Development of new pharmaceutical formulations based on using specific nano­scale carriers for improved drug delivery to target cells is one of crucial tasks of current pharmaceutics. Usage of such nanocomposites does not only extend the duration of action of drugs in the organism of patients, but also increases their bioavailability and, most importantly, reduces side effects of chemotherapy. We used nanocomplex based on fullerene C60 and well-known anticancer drug doxorubicin (Dx). It was found that immobilization of doxorubicin on fullerene C60 leads to 2–3 fold increase of the antineoplastic action of this drug in vitro towards various tumor cell lines compared with the effect of free doxorubicin. Cytomorphological studies have shown that the death of these tumor cells treated with this nanocomplex, occurs by apoptosis. Apoptosis induction by the action of C60-Dx complex is accompanied by the generation of superoxide radicals whose level increases significantly as soon as at the 1st hour after addition of this complex and reaches a maximum value in 3 hours. The obtained results suggest a prospectivity of application of fullerene-C60-doxorubicin complex in chemotherapy of malignant tumors.


Keywords


fullerene С60, doxorubicin, nanocomplex, reative oxygen species, apoptosis, cancer drug resistance

References


1. Матишевська О.П., Прилуцька С.В., Гринюк І.І. Фулерени С60 – біологічно активні молекули. I. Фізико-хімічні властивості та біодоступність. Біотехнологія, 2010; 3: 18–26.

2. Прилуцька С.В., Кічмаренко Ю.М., Богуцька К.І. та ін. Фулерен С60 та його похідні як протипухлинні агенти: проблеми і перспективи. Біотехнологія, 2012; 5(3): 9–17; Chenetal, 2012

3. Туров В.В., Угнивенко А.П., Барвинченко В.Н. и др. Строение гидратного слоя поверхности композитных систем SiO2/ДНК(Dox) и SiO2/ДНК(Dox)/фуллерен С60. Хімія, фізика та технологія поверхні, 2011; 2(2): 190–200.

4. Arbogast J.W., Darmanyan A.P., Foote C.S. et al. Photophysical properties of C60. J. Phys. Chem, 1991; 95: 11-2.
https://doi.org/10.1021/j100154a006

5. Balch A.L., Olmstead M.M. Structural chemistry of supramolecular assemblies that place flat molecular surfaces around the curved exteriors of fullerenes. Coord. Chem. Rev, 1999; 185-186: 601-617.
https://doi.org/10.1016/S0010-8545(99)00013-2

6. Bogdanovi G., Koji V., Dordevi A. et al. Modulating activity of fullerol C60(OH)22 on doxorubicin-induced cytotoxicity. Toxicol. In Vitro, 2004;18(5): 629-37.
https://doi.org/10.1016/j.tiv.2004.02.010
PMid:15251181

7. Boyd P.D.W., Reed C.A. Fullerene-porphyrin constructs. Acc. Chem. Res, 2005; 38: 235-242.
https://doi.org/10.1021/ar040168f
PMid:15835870

8. Burlaka А.P., Sidorik Е.P., Prylutska S.V. et al. Сatalytic system of the reactive oxygen species on the C60 fullerene basis. Exp. Oncol, 2004; 26(4); 326-327.

9. Chaudhuri P., Paraskar A., Soni S. et al. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano, 2009; Sep 22; 3(9): 2505-14.
https://doi.org/10.1021/nn900318y
PMid:19681636

10. Chen Z., Ma L., Liu Y. et al. Applications of functionalized fullerenes in tumor theranostics. Theranostics, 2012; 2(3): 238-250.
https://doi.org/10.7150/thno.3509
PMid:22509193 PMCid:PMC3326736

11. Davydenko M.O., Radchenko E.O., Yashchuk V.M. et al. Sensibilization of fullerene C60 immobilized at silica nanoparticles for cancer photodynamic therapy. J. Mol. Liq, 2006; 127(1-3): 145-147.
https://doi.org/10.1016/j.molliq.2006.03.046

12. Evstigneev M.P., Buchelnikov A.S., Voronin D.P. et al. Complexation of C60 fullerene with aromatic drugs. Chem. Phys. Chem, 2013: 4(3): 568-578.
https://doi.org/10.1002/cphc.201200938
PMid:23345058

13. Heister E., Neves V., Tilmaciu C. et al. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Сarbon, 2009; 47(9): 2152-2160.
https://doi.org/10.1016/j.carbon.2009.03.057

14. Injac R., Perse M., Cerne M. et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials, 2009 Feb; 30(6): 1184-96.
https://doi.org/10.1016/j.biomaterials.2008.10.060
PMid:19046599

15. Kroto H.W, Heath J.R, O'Brien S.C. et al C60-Buckminster fullerene. Nature, 1985; 318:162-3.
https://doi.org/10.1038/318162a0

16. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol, 1997; 40(7): 3-8.
https://doi.org/10.1007/s002800051053

17. Mikawa M., Kato H., Okumura M. et al. Paramagnetic Water-Soluble Metallofullerenes Having the Highest Relaxivity for MRI Contrast Agents. Bioconjugate Chem, 2001, 12, 510-514.
https://doi.org/10.1021/bc000136m
PMid:11459454

18. Minotti G., Menna P., Salvatorelli E. et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev, 2004 Jun; 56(2): 185-229.
https://doi.org/10.1124/pr.56.2.6
PMid:15169927

19. Prylutska S., Bilyy R., Overchuk M. et al. Water-soluble pristine fullerenes C60 increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. J. Biomed. Nanotechnol, 2012 Jun; 8(3): 522-7.
https://doi.org/10.1166/jbn.2012.1404
PMid:22764423

20. Prylutska S.V., Burlaka A.P., Klymenko P.P. et al. Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnol, 2011; 2(1): 105-110.
https://doi.org/10.1007/s12645-011-0020-x
PMid:26069489 PMCid:PMC4452036

21. Prylutska S.V., Burlaka A.P., Matyshevska O.P. et al. Effect of the visible light irradiation of fullerene-containing composites on the ROS generation and the viability of tumor cells. Exp. Oncol, 2006; 28(2): 160-162.

22. Prylutska S.V., Burlaka A.P., Prylutskyy Yu.I. et al. Comparative study of antitumor effect of pristine C60 fullerenes and doxorubicin. Biotechnologia Acta, 2011; 4(6): 82-87.

23. Prylutska S.V., Burlaka A.P., Prylutskyy Yu.I. et al. Pristine C60 fullerenes inhibit the rate of tumor growth and metastasis. Exp. Oncol, 2011; 33(3): 162-164.

24. Scharff P., Risch K., Carta-Abelmann L. et al. Structure of C60 fullerene in water: spectroscopic data. Carbon, 2004; 42(5-6): 1203-1206.
https://doi.org/10.1016/j.carbon.2003.12.053

25. Young R.C. In: Drug resistance in cancer therapy. Kluwer, Dordrecht; 1989, 1-26.
https://doi.org/10.1007/978-1-4613-1601-5_1
PMid:2577131

26. Zakharian T.Y., Seryshev A., Sitharaman B. et al. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J. Am. Chem. Soc, 2005 Sep 14; 127(36): 12508-9.
https://doi.org/10.1021/ja0546525
PMid:16144396


Refbacks

  • There are currently no refbacks.


Copyright (c) 2013 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.